Health Economics and Pharmacoeconomics Opportunities for German - African Cooperation

Kalendereintrag speichern


  • Nathalie Dehne, Head of Deanery, Faculty of Health Sciences Brandenburg, Potsdam, Germany
  • Cornelius Frömmel, Dean and Professor, Faculty of Health Sciences Brandenburg, Potsdam, Germany
  • Ntobeko Mpanza, Director, Pharmaceutical Economic Evaluations Directorate, National Department of Health, South Africa
  • Günter Peine, Advisor Transfer und Translation, Faculty of Health Sciences Brandenburg, Potsdam, Germany
  • Bernd Rosenkranz, President, Fundisa African Academy of Medicines Development, Cape Town; Professor emeritus, Division of Clinical Pharmacology, Stellenbosch University, South Africa; Charité Universitätsmedizin Berlin, Germany
  • Michael Thiede, Director, Scenarium Group GmbH and Professor of Business Economics and Health Care Management, International University of Applied Sciences, Berlin, Germany
  • Praneet Valodia, Adjunct Professor, University of the Western Cape; Director, Praneet Valodia Consulting, Cape Town, South Africa

VENUE: Hybrid workshop—University of Potsdam, Germany (Auditorium Maximum), plus online participation Attendance is free, but registration is required.

Africa is one of the world’s fastest-growing economic regions. In addition to multinational companies active on the African continent, an increasing number of local companies engage in the development, production and marketing of medicines, medical devices and diagnostics across Africa. There are many examples of successful partnerships between German and African stakeholders.

Health technology assessment (HTA) plays an increasing role in decision-making in product development, licencing, pricing and reimbursement. Pharmacoeconomic modelling methods are also used as bridging tools between clinical phase 3 efficacy data and “real world” outcomes. It is therefore important that pharmaceutical companies engaged in Africa have an understanding of this “fourth hurdle” to market access in order to optimise the potential of their medicines in this region. HTA also plays an essential role in decision-making as well as designing policies on the use of medical devices – with a view to the efficient use of resources in health care.

At this workshop, recognised experts from Europe and Africa will explore potential use and applications of pharmacoeconomic tools for medicines, medical devices and diagnostics.

The workshop will emphasise upcoming trends in HTA in light of health systems strengthening towards universal health coverage. The format will provide an opportunity for networking between various stakeholders and for capacity building.



  • Awareness of methodologies, outcomes and implications of health technology assessments for medicines, medical devices and diagnostics
  • Opportunity for networking between experts from industry, academia, and health technology assessment agencies
  • Capacity building for young scientists
  • Cooperation between German and African partners


  • Experts in health economics from industry (medicines, medical devices and diagnostics), academia, funders/payers, and health technology assessment agencies
  • Government officials
  • Consumers (patient organisations)
  • Postgraduate students


30 October 2021 (Day 1):

14:00 Introduction

Official welcome

Keynote speakers

Sandile S. S. Buthelezi, Director General, South African National Department of Health – African perspective To be confirmed – European perspective


16:00 Pharmacoeconomics in health systems strengthening - Panel discussion

Introduction: Linking pharmacoeconomics to health system strengthening (Alric Ruether, Head of International Affairs, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany)

Participants: HTA agency representatives/experts, funders/payers, consumer groups from Africa and Europe

18:00 End of session

31 October 2021 (Day 2):

09:00 Trends and methods in health economics

Pharmacoeconomic modelling (Johanna Lister, Takeda, Global Pricing and Access, Global Health Economics Lead, Zuerich, Switzerland)

Total-cost-of-care models (Praneet Valodia, University of the Western Cape and Praneet Valodia Consulting, Cape Town, South Africa)

Provision of oncological care in selected African countries (Christine Holmberg, Head, Institute for Social Medicine and Epidemiology, Fontane Medical School, Brandenburg, Germany)

Advancing cancer care in Africa via public-private-partnerships - the perspective of the biopharmaceutical industry (Ruth Field, AstraZeneca, Director Market Access Oncology, Respiratory, Cardiometabolic, Diabetes & General Medicine, Bryanston, South Africa)

Using cost models and pharmacoeconomics in supporting COVID-19 decision making (Jacqui Miot, Division Director, Health Economics & Epidemiology Research Office, School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa)

Pharmacoeconomics in neglected tropical diseases: the case of mycetoma (Ed Zijlstra, Drugs for Neglected Diseases Initiative, DNDi, Geneva, Switzerland)

Establishment of SARS-CoV-2 diagnostic facilities in Africa – Example of German-Africa cooperation (Tom Halgasch, Das Labor Potsdam, Germany)

Health Technology Assessments (HTAs) of medical technologies (medical devices, equipment and in vitro diagnostics)


11:30 Trends in health economics - Panel discussion


13:30 Capacity Building: Cross-Country Collaboration

Comprehensive capacity building needs assessment (Susan Cleary, Health Economics Unit, University of Cape Town, South Africa)

Capacity building initiatives, examples from Africa

East Africa (Vincent Okungu, United Nations Institute for Training and Research, Kigali, Rwanda)

South Africa (to be confirmed) Scientific capacity building in academia across sub-Saharan Africa (Karl Collins, Director, Science Program, Bayer Foundation, Leverkusen, Germany)

Panel Discussion


15:00 Global Collaboration in Health Economics from an African Perspective

Country experience: South Africa Policy position of the Pricing Committee on Health Technology Assessment in South Africa (Neo Kitsa, Chair, Pricing Committee, South African National Department of Health, Pretoria, South Africa) The role of Health Technology Assessment under the National Health Insurance (NHI) in South Africa (Nicholas Crisp, Deputy Director General, National Health Insurance, South African National Department of Health, Pretoria, South Africa) Essential Medicines List (EML) (Marc Blockman, Division of Clinical Pharmacology, University of Cape Town, South Africa)

Country experience: Ghana

The role of Health Technology Assessment under the National Health Insurance (NHI) in Ghana (Patricia Akweongo, Head, Department of Health Policy, Planning and Management, School of Public Health, University of Ghana)

Country experience: Kenya

Health economics considerations in Kenya (Bernhards Ogutu, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya)

Industry experience: to be confirmed

Panel Discussion

16:30 Invited speaker: Innovative concepts and global perspectives

18:00 Concluding remarks